https://ainhibitor.com/lncrna-....mcf2l-as1-exacerbate
Four adjuvant phase III randomized trials from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) study groups provided individual patient-level data for this analysis. We investigated the effect of endocrine resistance/sensitivity classification on overall survival (mOS, defined as the duration from distant relapse to death) via univariate and multivariate Cox proportional haza
Like
Comment
Share
